Quarterly report pursuant to Section 13 or 15(d)

Liquidity and Going Concern Disclosure

Liquidity and Going Concern Disclosure
3 Months Ended
Jun. 30, 2017
Liquidity and Going Concern Disclosure



As of June 30, 2017, the Company had a working capital deficit of approximately $1,131,769 million and losses from operations of approximately $287,925.


The Company typically raises capital which it spends on maintaining its research and corporate operations.  At this early stage in the life of the Company funding is often short term in nature. While the Company has been proficient in raising funds in the past the short term nature of these funding cycles raises substantial doubt about the Company's ability to continue as a going concern within one year from the date of this filing.


Management is addressing going concern risk by seeking new sources of capital and is continuing initiatives to raise capital through private placements, related party loans and other institutional sources to meet future working capital requirements.  Furthermore, strategic partnerships, most likely with larger pharmaceutical industry companies, will be needed to continue to fund research and development costs as our projects expand. These measures, if successful, may contribute to reduce the risk of going concern uncertainties for the Company for at least twelve months from issuance of these consolidated financial statements.


The ability of the Company to continue as a going concern is dependent upon its ability to raise additional capital and achieve profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.